ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arrowhead Pharmaceuticals Inc (ARWR) is not a strong buy at the moment for a beginner investor with a long-term focus. While the technical indicators show some bullish trends, the lack of significant positive catalysts, mixed analyst ratings, and weak financial performance in the latest quarter suggest caution. The investor should monitor the stock for future developments, particularly the Phase 3 data expected in Q3 2026, which could unlock value.
The technical indicators show a mixed picture. The MACD is positive and contracting, indicating a potential bullish trend. The RSI is neutral at 62.511, and moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Key support is at 60.486, and resistance is at 70.365. However, the stock has declined by 4.19% in the regular market session, suggesting some short-term weakness.
Analysts from BofA and H.C. Wainwright maintain a Buy rating with price targets of $81 and $100, respectively, citing potential value unlock from APOC3 sHTG opportunity and obesity growth pillar.
The stock has a 90% chance of gaining 10.93% in the next month based on historical patterns.
Mixed competitor data and questions around INHBE expectations have raised concerns, as highlighted by Leerink.
Financial performance in Q1 2026 shows a significant drop in net income (-117.80% YoY) and EPS (-115.83% YoY), despite a massive revenue increase.
In Q1 2026, revenue increased significantly by 10461.32% YoY to $264.03M. However, net income dropped by -117.80% YoY to $30.81M, and EPS fell by -115.83% YoY to $0.22. Gross margin remained stable at 100%. The financials indicate strong revenue growth but poor profitability.
Analyst sentiment is mixed. BofA and H.C. Wainwright maintain a Buy rating with high price targets, while Morgan Stanley and Leerink are more cautious with Market Perform and Equal Weight ratings. Price targets range from $78 to $101, with a focus on upcoming Phase 3 data as a key catalyst.
